Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification
Jakub Trizuljak(Masaryk University), Akif Selim Yavuz(Istanbul University), Björn van Anrooij(University Medical Center Groningen), Jens Panse(University Hospital Cologne), Knut Brockow(Technical University of Munich), Mattias Mattsson(Uppsala University Hospital), Nadja Jäkel(University Hospital in Halle), Lucie Nekvindová(Masaryk University), Marek Niedoszytko(Gdańsk Medical University), Michael Doubek(Central European Institute of Technology), Hanneke C. Kluin‐Nelemans(University Medical Center Groningen), Karoline V. Gleixner(Medical University of Vienna), Francesca Caroppo(University of Padua), Vito Sabato(Antwerp University Hospital), Anna Belloni Fortina(University of Padua), Massimo Triggiani, Aleksandra Górska(Gdańsk Medical University), Jiřı́ Mayer(Masaryk University), Khalid Shoumariyeh(University of Freiburg), Anja Illerhaus(University of Cologne), Olivier Hermine(Centre National de la Recherche Scientifique), Agnes Bretterklieber(Graz University Hospital), Jason Gotlib(Stanford University), Nikolas von Bubnoff(Universitäres Kinderwunschzentrum Lübeck), Cecelia Perkins(Stanford Cancer Institute), Massimiliano Bonifacio(University of Verona), Luca Malcovati(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Wolfgang R. Sperr(Medical University of Vienna), Roberta Parente(University of Salerno), David Fuchs, Karin Hartmann(University Hospital of Basel), Hanneke Oude Elberink(University Medical Center Groningen), Alex Kilbertus, Roberta Zanotti(University of Verona), Mohamad Jawhar(Heidelberg University), Patrizia Bonadonna(Azienda Ospedaliera Universitaria Integrata Verona), Hans Hägglund(Uppsala University Hospital), Magdalena Lange(Gdańsk Medical University), Andreas Reiter(Heidelberg University)
Cited by 77
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k